MOONLAKE IMMUNOTHERAPEUTICS (MLTX) 8-K Summary

Date of Event: November 5, 2025

MoonLake Immunotherapeutics announced the issuance of a press release covering two major areas:

1. Financial Performance (Item 2.02): Release of financial results for the quarter ended September 30, 2025.
2. Clinical Updates (Item 7.01): Disclosure of significant clinical data regarding Sonelokimab (SLK):
   • Phase 2 results for SLK in palmoplantar pustulosis (LEDA trial).
   • Interim analysis from the Phase 3 VELA-TEEN trial (SLK in adolescent hidradenitis suppurativa).

All mater